Ted Drogendijk

2.1k citations

22 papers · 1.6k indexed · 1 hit paper · h-index 13

Impact in

Urology top 0.2%
- Urinary Bladder and Prostate Research
- Urological Disorders and Treatments
Rheumatology top 0.5%
- Pelvic floor disorders treatments

Papers in ⓘ

Urology 17
- Urinary Bladder and Prostate Research 17
Epidemiology 13
- Urinary Tract Infections Management 13

Co-authors: Christopher R. Chapple (9 shared papers)John Bolodeoku (4 shared papers)Arwin Ridder (3 shared papers)Peter J. Boerrigter (2 shared papers)L. Cardozo (3 shared papers)Igor V. Kuzmin (2 shared papers)Nancy Martin (2 shared papers)G. Amarenco (3 shared papers)
Journals: European Urology (5 papers)Urology (3 papers)British Journal of Urology (3 papers)Value in Health (2 papers)The Journal of Urology (1 paper)
Partner nations: Netherlands United Kingdom Japan

In The Last Decade

Ted Drogendijk

22 papers receiving 1.5k citations

Hit Papers

align trajectories log scale

Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial 2012 · 329 citations

Peers

Countries citing papers authored by Ted Drogendijk

Since Specialization

Citations

This map shows the geographic impact of Ted Drogendijk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ted Drogendijk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ted Drogendijk more than expected).

Fields of papers citing papers by Ted Drogendijk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ted Drogendijk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ted Drogendijk. The network helps show where Ted Drogendijk may publish in the future.

Co-authors

The 25 scholars most cited alongside Ted Drogendijk, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ted Drogendijk Line = papers co-authored together Ted Drogendijk links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial European Urology ·Vik Khullar, G. Amarenco, J.C. Angulo, J. Cambronero, Kjetil Høye, Ian Milsom, Piotr Radziszewski, Tomasz Rechberger, Peter J. Boerrigter, Ted Drogendijk, M. Wooning, Christopher R. Chapple Hit paper breakdown →	2012	329
2	RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF THE ONCE DAILY ANTIMUSCARINIC AGENT SOLIFENACIN SUCCINATE IN PATIENTS WITH OVERACTIVE BLADDER The Journal of Urology ·L. Cardozo, M. LISEC, R. J. Millard, Oncko Van Vierssen Trip, Igor V. Kuzmin, Ted Drogendijk, Moses Huang, Arwin Ridder	2004	250
3	A Comparison of the Efficacy and Tolerability of Solifenacin Succinate and Extended Release Tolterodine at Treating Overactive Bladder Syndrome: Results of the STAR Trial European Urology ·Christopher R. Chapple, R. Martínez-García, Luigi Selvaggi, Philip Toozs‐Hobson, W. Warnack, Ted Drogendijk, D.M. Wright, John Bolodeoku	2005	246
4	Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive Bladder European Urology ·Christopher R. Chapple, Steven A. Kaplan, David Mitcheson, Jiří Klečka, Jana Cummings, Ted Drogendijk, Caroline A. Dorrepaal, Nancy Martin	2012	243
5	Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double‐blind, placebo‐controlled, rising‐dose trial British Journal of Urology ·Linda Cardozo, Elke Heßdörfer, Rodolfo Milani, Pedro Arañó, Luc Dewilde, Mark Slack, Ted Drogendijk, Mark Wright, John Bolodeoku, (unknown)	2008	111
6	A phase II dose-ranging study of mirabegron in patients with overactive bladder International Urogynecology Journal ·(unknown), Christopher R. Chapple, Vladimír Dvořák, P. Radziszewski, Philip Van Kerrebroeck, Jean Jacques Wyndaele, Brigitte Bosman, Peter J. Boerrigter, Ted Drogendijk, Arwin Ridder, Ingrid van der Putten-Slob, Osamu Yamaguchi	2013	107
7	Combination Therapy with Solifenacin and Tamsulosin Oral Controlled Absorption System in a Single Tablet for Lower Urinary Tract Symptoms in Men: Efficacy and Safety Results from the Randomised Controlled NEPTUNE Trial European Urology ·Philip Van Kerrebroeck, Christopher R. Chapple, Ted Drogendijk, Monique Klaver, Roman Sokol, Mark Speakman, Klaudia Traudtner, Marcus J. Drake	2013	69
8	Long-term Safety and Efficacy of Single-tablet Combinations of Solifenacin and Tamsulosin Oral Controlled Absorption System in Men with Storage and Voiding Lower Urinary Tract Symptoms: Results from the NEPTUNE Study and NEPTUNE II Open-label Extension European Urology ·Marcus J. Drake, Christopher R. Chapple, Roman Sokol, Matthias Oelke, Klaudia Traudtner, Monique Klaver, Ted Drogendijk, Philip Van Kerrebroeck	2014	48
9	Single dose pharmacokinetics and absolute bioavailability of mirabegron, a ?3-adrenoceptor agonist for treatment of overactive bladder International Journal of Clinical Pharmacology and Therapeutics ·Charlotte Eltink, Jennifer Lee, Marloes Schaddelee, Wenhui Zhang, Virginie Kerbusch, John Meijer, Sjoerd van Marle, Nicole Grunenberg, Donna Kowalski, Ted Drogendijk, Selina Moy, Hiromi Iitsuka, Marcel van Gelderen, Hiroshi Matsushima, Taiji Sawamoto	2012	42
10	Total urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptoms British Journal of Urology ·Christopher R. Chapple, Marcus J. Drake, Philip Van Kerrebroeck, Linda Cardozo, Ted Drogendijk, Monique Klaver, K. Van Charldorp, Zalmaï Hakimi, Gerhard Compion	2013	29
11	Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine European Journal of Cancer ·L. Pronk, André Planting, R. Oosterom, Ted Drogendijk, G. Stoter, Jaap Verweij	1994	27
12	Severity of overactive bladder symptoms and response to dose escalation in a randomized, double‐blind trial of solifenacin ( SUNRISE ) British Journal of Urology ·Linda Cardozo, G. Amarenco, Pushkar' DIu, Jura Mikulas, Ted Drogendijk, Mark Wright, Gerhard Compion, (unknown)	2013	26
13	The effects of an ACTH (4?9) analogue on development of cisplatin neuropathy in testicular cancer: A randomized trial Journal of Neurology ·Joop van Gerven, A. Hovestadt, J. Moll, C. J. Rodenburg, Ted A.W. Splinter, A.T. van Oosterom, Laura de Keizer, Ted Drogendijk, C. Groenhout, Ch.J. Vecht, J.P. Neijt	1994	23
14	683 Randomised, double-blind, active-controlled phase III study to assess the long-term safety and efficacy of mirabegron in overactive bladder (OAB) European Urology Supplements ·Christopher R. Chapple, S.A. Kaplan, H.D. Mitcheson, Jiří Klečka, Joanne Cummings, Ted Drogendijk, Caroline A. Dorrepaal, Nancy Martin	2012	11
15	Validation of the Patient Perception of Intensity of Urgency Scale in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia Value in Health ·Susan D. Mathias, Ross D. Crosby, Jameel Nazir, Monique Klaver, Ted Drogendijk, Zalmaï Hakimi, Isaac Odeyemi	2014	10
16	YM905: Results of a randomised, double-blind placebo-controlled trial in patients with symptomatic overactive bladder European Urology Supplements ·L. Cardozo, Igor V. Kuzmin, M.L. Lisee, R. J. Millard, Oncko B. van Vierssen Trip, Arwin Ridder, Ted Drogendijk	2003	7
17	UP-2.35: Total urgency score (TUS) as a measure of frequency and urgency in SUNRISE Urology ·L. Cardozo, Jura Mikulas, G. Amarenco, Ted Drogendijk, Gerhard Compion	2010	5
18	POS-01.134: Responses to solifenacin in patients >65 years and ≤65 years with overactive bladder syndrome: post-hoc results from the randomised, double-blind STAR study Urology ·Christopher R. Chapple, Ted Drogendijk, D.M. Wright, John Bolodeoku	2007	3
19	1089 Quality of life analyses from NEPTUNE, a phase 3 trial of combination therapy with tamsulosin OCAS™ and solifenacin in men with lower urinary tract symptoms European Urology Supplements ·Marcus J. Drake, Roman Sokol, Monique Klaver, Ted Drogendijk, Zalmaï Hakimi, Isaac Odeyemi, P.E.V. Van Kerrebroeck	2013	3
20	The efficacy of solifenacin 5/10mg on ‘urgency’ endpoints in different OAB patient populations: subanalysis of results from the randomised, double-blind SUNRISE study Linda Cardozo, Ted Drogendijk, John Bolodeoku	2008	2

About Ted Drogendijk

Ted Drogendijk is a scholar working on Urology, Epidemiology, Rheumatology, Surgery and Pulmonary and Respiratory Medicine, having authored 22 papers that have together received 1.6k indexed citations. Recurring topics across this work include Urinary Bladder and Prostate Research (17 papers), Urinary Tract Infections Management (13 papers), Pelvic floor disorders treatments (13 papers), Prostate Cancer Diagnosis and Treatment (2 papers), Cardiovascular Syncope and Autonomic Disorders (1 paper), Cancer Treatment and Pharmacology (1 paper), Bone health and treatments (1 paper) and Health Systems, Economic Evaluations, Quality of Life (1 paper). The work is most often cited by research in Urology (1.4k citations), Rheumatology (1.2k citations), Epidemiology (916 citations), Gastroenterology (58 citations) and Endocrinology, Diabetes and Metabolism (131 citations). Ted Drogendijk has collaborated with scholars based in Netherlands, United Kingdom and Japan. Frequent co-authors include Christopher R. Chapple, John Bolodeoku, Arwin Ridder, Peter J. Boerrigter, L. Cardozo, Igor V. Kuzmin, Nancy Martin, G. Amarenco, D.M. Wright and Caroline A. Dorrepaal. Their work appears in journals such as European Urology, Urology, British Journal of Urology, Value in Health and The Journal of Urology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact